Pediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management
The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Abstract
Gliomas are the most common CNS tumors in children and adolescents, and they show an extremely broad range of clinical behavior. The majority of pediatric gliomas present as benign, slow-growing lesions classified as grade I or II by the WHO classification of CNS tumors. These pediatric low-grade gliomas (LGGs) are fundamentally different from IDH-mutant LGGs occurring in adults, because they rarely undergo malignant transformation and show excellent overall survival under current treatment strategies. However, a significant fraction of gliomas develop over a short period of time and progress rapidly and are therefore classified as WHO grade III or IV high-grade gliomas (HGGs). Despite all therapeutic efforts, they remain largely incurable, with the most aggressive forms being lethal within months. Thus, the intentions of neurosurgeons, pediatric oncologists, and radiotherapists to improve care for pediatric patients with glioma range from increasing quality of life and preventing long-term sequelae in what is often a chronic, but rarely life-threatening disease (LGG), to uncovering effective treatment options to prolong patient survival in an almost universally fatal setting (HGG). The last decade has seen unprecedented progress in understanding the molecular biology underlying pediatric gliomas, fueling hopes to achieve both goals. Large-scale collaborative studies around the globe have cataloged genomic and epigenomic alterations in gliomas across ages, grades, and histologies. These studies have revealed biologic subgroups characterized by distinct molecular, pathologic, and clinical features, with clear relevance for patient management. In this review, we summarize hallmark discoveries that have expanded our knowledge in pediatric LGGs and HGGs, explain their role in tumor biology, and convey our current concepts on how these findings may be translated into novel therapeutic approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
Schwartzentruber, J., Korshunov, A., Liu, X.-Y., Jones, D. T. W., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A. M., Quang, D.-A. K., Tönjes, M., et al. (2012) · Nature · doi:10.1038/nature10833 · Cited by 2,631 · cited 4×
“tumors.(46,49) Other molecular features include a high percentage of TP53 mutations (.”
BackgroundInfluentialSelf-citationCeccarelli, M., Barthel, F. P., Malta, T. M., Sabedot, T. S., Salama, S. R., Murray, B. A., Morozova, O., Newton, Y., Radenbaugh, A., Pagnotta, S. M., et al. (2016) · Cell · doi:10.1016/j.cell.2015.12.028 · Cited by 2,189
Sturm, D., Witt, H., Hovestadt, V., Khuong-Quang, D.-A., Jones, D. T. W., Konermann, C., Pfaff, E., Tönjes, M., Sill, M., Bender, S., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.024 · Cited by 1,828
Self-citationSt. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2012) · Nature Genetics · doi:10.1038/ng.1102 · Cited by 1,724
Northrup, H., Krueger, D. A., Northrup, H., Krueger, D. A., Roberds, S., Smith, K., Sampson, J., Korf, B., Kwiatkowski, D. J., Mowat, D., et al. (2013) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2013.08.001 · Cited by 1,502
Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma
Lewis, P. W., Müller, M. M., Koletsky, M. S., Cordero, F., Lin, S., Banaszynski, L. A., Garcia, B. A., Muir, T. W., Becher, O. J., & Allis, C. D. (2013) · Science · doi:10.1126/science.1232245 · Cited by 1,345 · cited 1×
“Original data from the German Cancer Research Center in Heidelberg aligned with published data from other studies.(2,39-46,48,49,52-55,63-65) amp.”
ResultOstrom, Q. T., Gittleman, H., Xu, J., Kromer, C., Wolinsky, Y., Kruchko, C., & Barnholtz-Sloan, J. S. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now207 · Cited by 1,204
the St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2014) · Nature Genetics · doi:10.1038/ng.2938 · Cited by 1,105
Schindler, G., Capper, D., Meyer, J., Janzarik, W., Omran, H., Herold-Mende, C., Schmieder, K., Wesseling, P., Mawrin, C., Hasselblatt, M., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0802-6 · Cited by 1,034
Self-citationKhuong-Quang, D.-A., Buczkowicz, P., Rakopoulos, P., Liu, X.-Y., Fontebasso, A. M., Bouffet, E., Bartels, U., Albrecht, S., Schwartzentruber, J., Letourneau, L., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0998-0 · Cited by 1,028
Self-citationNew Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs
Sturm, D., Orr, B. A., Toprak, U. H., Hovestadt, V., Jones, D. T. W., Capper, D., Sill, M., Buchhalter, I., Northcott, P. A., Leis, I., et al. (2016) · Cell · doi:10.1016/j.cell.2016.01.015 · Cited by 975
Self-citationJones, D. T. W., Kocialkowski, S., Liu, L., Pearson, D. M., Bäcklund, L. M., Ichimura, K., & Collins, V. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2097 · Cited by 944
Self-citationBouffet, E., Larouche, V., Campbell, B. B., Merico, D., de Borja, R., Aronson, M., Durno, C., Krueger, J., Cabric, V., Ramaswamy, V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.6552 · Cited by 857
Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas
the St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2013) · Nature Genetics · doi:10.1038/ng.2611 · Cited by 835
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma
the International Cancer Genome Consortium PedBrain Tumor Project, Jones, D. T. W., Hutter, B., Jäger, N., Korshunov, A., Kool, M., Warnatz, H.-J., Zichner, T., Lambert, S. R., Ryzhova, M., et al. (2013) · Nature Genetics · doi:10.1038/ng.2682 · Cited by 825
Self-citationBender, S., Tang, Y., Lindroth, A. M., Hovestadt, V., Jones, D. T. W., Kool, M., Zapatka, M., Northcott, P. A., Sturm, D., Wang, W., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.10.006 · Cited by 818
Self-citationFranz, D. N., Belousova, E., Sparagana, S., Bebin, E. M., Frost, M., Kuperman, R., Witt, O., Kohrman, M. H., Flamini, J. R., Wu, J. Y., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61134-9 · Cited by 794
Activity of Selumetinib in Neurofibromatosis Type 1–Related Plexiform Neurofibromas
Dombi, E., Baldwin, A., Marcus, L. J., Fisher, M. J., Weiss, B., Kim, A., Whitcomb, P., Martin, S., Aschbacher-Smith, L. E., Rizvi, T. A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1605943 · Cited by 682
Castel, D., Philippe, C., Calmon, R., Le Dret, L., Truffaux, N., Boddaert, N., Pagès, M., Taylor, K. R., Saulnier, P., Lacroix, L., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1478-0 · Cited by 664
Paugh, B. S., Qu, C., Jones, C., Liu, Z., Adamowicz-Brice, M., Zhang, J., Bax, D. A., Coyle, B., Barrow, J., Hargrave, D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7252 · Cited by 654
Buczkowicz, P., Hoeman, C., Rakopoulos, P., Pajovic, S., Letourneau, L., Dzamba, M., Morrison, A., Lewis, P., Bouffet, E., Bartels, U., et al. (2014) · Nature Genetics · doi:10.1038/ng.2936 · Cited by 647
Diffuse brainstem glioma in children: critical review of clinical trials
Hargrave, D., Bartels, U., & Bouffet, E. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70615-5 · Cited by 634
Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge
Sturm, D., Bender, S., Jones, D. T. W., Lichter, P., Grill, J., Becher, O., Hawkins, C., Majewski, J., Jones, C., Costello, J. F., et al. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3655 · Cited by 555
Self-citationRecurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma
Taylor, K. R., Mackay, A., Truffaux, N., Butterfield, Y. S., Morozova, O., Philippe, C., Castel, D., Grasso, C. S., Vinci, M., Carvalho, D., et al. (2014) · Nature Genetics · doi:10.1038/ng.2925 · Cited by 517
Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma
Hashizume, R., Andor, N., Ihara, Y., Lerner, R., Gan, H., Chen, X., Fang, D., Huang, X., Tom, M. W., Ngo, V., et al. (2014) · Nature Medicine · doi:10.1038/nm.3716 · Cited by 476
Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma
Fontebasso, A. M., Papillon-Cavanagh, S., Schwartzentruber, J., Nikbakht, H., Gerges, N., Fiset, P.-O., Bechet, D., Faury, D., De Jay, N., Ramkissoon, L. A., et al. (2014) · Nature Genetics · doi:10.1038/ng.2950 · Cited by 465
Self-citationSolomon, D. A., Wood, M. D., Tihan, T., Bollen, A. W., Gupta, N., Phillips, J. J. J., & Perry, A. (2016) · Brain Pathology · doi:10.1111/bpa.12336 · Cited by 433
Ater, J. L., Zhou, T., Holmes, E., Mazewski, C. M., Booth, T. N., Freyer, D. R., Lazarus, K. H., Packer, R. J., Prados, M., Sposto, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.6054 · Cited by 433
Qaddoumi, I., Orisme, W., Wen, J., Santiago, T., Gupta, K., Dalton, J. D., Tang, B., Haupfear, K., Punchihewa, C., Easton, J., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1539-z · Cited by 409
Cohen, K. J., Pollack, I. F., Zhou, T., Buxton, A., Holmes, E. J., Burger, P. C., Brat, D. J., Rosenblum, M. K., Hamilton, R. L., Lavey, R. S., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq191 · Cited by 399
von Recklinghausen Neurofibromatosis
Lewis, R. A., Gerson, L. P., Axelson, K. A., Riccardi, V. M., & Whitford, R. P. (1984) · Ophthalmology · doi:10.1016/s0161-6420(84)34217-8 · Cited by 354
Korshunov, A., Ryzhova, M., Hovestadt, V., Bender, S., Sturm, D., Capper, D., Meyer, J., Schrimpf, D., Kool, M., Northcott, P. A., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1405-4 · Cited by 350
Self-citationBuczkowicz, P., Bartels, U., Bouffet, E., Becher, O., & Hawkins, C. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1319-6 · Cited by 350
Worst, B. C., van Tilburg, C. M., Balasubramanian, G. P., Fiesel, P., Witt, R., Freitag, A., Boudalil, M., Previti, C., Wolf, S., Schmidt, S., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.06.009 · Cited by 330
Self-citationJones, D. T. W., Kocialkowski, S., Liu, L., Pearson, D. M., Ichimura, K., & Collins, V. P. (2009) · Oncogene · doi:10.1038/onc.2009.73 · Cited by 321
Self-citationPaugh, B. S., Broniscer, A., Qu, C., Miller, C. P., Zhang, J., Tatevossian, R. G., Olson, J. M., Geyer, J. R., Chi, S. N., da Silva, N. S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5677 · Cited by 320
Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN
Bjerke, L., Mackay, A., Nandhabalan, M., Burford, A., Jury, A., Popov, S., Bax, D. A., Carvalho, D., Taylor, K. R., Vinci, M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0426 · Cited by 318
Zarghooni, M., Bartels, U., Lee, E., Buczkowicz, P., Morrison, A., Huang, A., Bouffet, E., & Hawkins, C. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.5463 · Cited by 313
Mistry, M., Zhukova, N., Merico, D., Rakopoulos, P., Krishnatry, R., Shago, M., Stavropoulos, J., Alon, N., Pole, J. D., Ray, P. N., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3922 · Cited by 288
Sievert, A. J., Lang, S.-S., Boucher, K. L., Madsen, P. J., Slaunwhite, E., Choudhari, N., Kellet, M., Storm, P. B., & Resnick, A. C. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219232110 · Cited by 285
Gnekow, A. K., Falkenstein, F., von Hornstein, S., Zwiener, I., Berkefeld, S., Bison, B., Warmuth-Metz, M., Driever, P. H., Soerensen, N., Kortmann, R.-D., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos202 · Cited by 279
MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism
Bandopadhayay, P., Ramkissoon, L. A., Jain, P., Bergthold, G., Wala, J., Zeid, R., Schumacher, S. E., Urbanski, L., O'Rourke, R., Gibson, W. J., et al. (2016) · Nature Genetics · doi:10.1038/ng.3500 · Cited by 277
Epithelioid GBMs Show a High Percentage of BRAF V600E Mutation
Kleinschmidt-DeMasters, B. K., Aisner, D. L., Birks, D. K., & Foreman, N. K. (2013) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31827f9c5e · Cited by 260
Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma
Nikbakht, H., Panditharatna, E., Mikael, L. G., Li, R., Gayden, T., Osmond, M., Ho, C.-Y., Kambhampati, M., Hwang, E. I., Faury, D., et al. (2016) · Nature Communications · doi:10.1038/ncomms11185 · Cited by 252
Puget, S., Philippe, C., Bax, D. A., Job, B., Varlet, P., Junier, M.-P., Andreiuolo, F., Carvalho, D., Reis, R., Guerrini-Rousseau, L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030313 · Cited by 242
Korshunov, A., Capper, D., Reuss, D., Schrimpf, D., Ryzhova, M., Hovestadt, V., Sturm, D., Meyer, J., Jones, C., Zheludkova, O., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1493-1 · Cited by 236
Self-citationNovel Oncogenic PDGFRA Mutations in Pediatric High-Grade Gliomas
Paugh, B. S., Zhu, X., Qu, C., Endersby, R., Diaz, A. K., Zhang, J., Bax, D. A., Carvalho, D., Reis, R. M., Onar-Thomas, A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1491 · Cited by 235 · cited 2×
“Other subgroups are enriched for amplifications or mutations in receptor tyrosine kinase genes such as PDGFRA or EGFR.(49,65,69) Initial evidence points toward possible prognostic differences in these subsets.”
BackgroundRecurrent MET fusion genes represent a drug target in pediatric glioblastoma
International Cancer Genome Consortium PedBrain Tumor Project (2016) · Nature Medicine · doi:10.1038/nm.4204 · Cited by 233
Diffuse intrinsic pontine gliomas: A systematic update on clinical trials and biology
Jansen, M. H. A., van Vuurden, D. G., Vandertop, W. P., & Kaspers, G. J. L. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.06.007 · Cited by 232
Survival and long-term health and cognitive outcomes after low-grade glioma
Armstrong, G. T., Conklin, H. M., Huang, S., Srivastava, D., Sanford, R., Ellison, D. W., Merchant, T. E., Hudson, M. M., Hoehn, M. E., Robison, L. L., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq178 · Cited by 227
Ramkissoon, L. A., Horowitz, P. M., Craig, J. M., Ramkissoon, S. H., Rich, B. E., Schumacher, S. E., McKenna, A., Lawrence, M. S., Bergthold, G., Brastianos, P. K., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300252110 · Cited by 227
Faury, D., Nantel, A., Dunn, S. E., Guiot, M.-C., Haque, T., Hauser, P., Garami, M., Bognár, L., Hanzély, Z., Liberski, P. P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.8626 · Cited by 225
Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas
Karajannis, M. A., Legault, G., Fisher, M. J., Milla, S. S., Cohen, K. J., Wisoff, J. H., Harter, D. H., Goldberg, J. D., Hochman, T., Merkelson, A., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou059 · Cited by 223
Self-citationStokland, T., Liu, J.-F., Ironside, J. W., Ellison, D. W., Taylor, R., Robinson, K. J., Picton, S. V., & Walker, D. A. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq092 · Cited by 206
Raabe, E. H., Lim, K. S., Kim, J. M., Meeker, A., Mao, X.-G., Nikkhah, G., Maciaczyk, J., Kahlert, U., Jain, D., Bar, E., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3349 · Cited by 198
Nicholson, H. S., Kretschmar, C. S., Krailo, M., Bernstein, M., Kadota, R., Fort, D., Friedman, H., Harris, M. B., Tedeschi‐Blok, N., Mazewski, C., et al. (2007) · Cancer · doi:10.1002/cncr.22961 · Cited by 196
Germline and somatic FGFR1 abnormalities in dysembryoplastic neuroepithelial tumors
Rivera, B., Gayden, T., Carrot-Zhang, J., Nadaf, J., Boshari, T., Faury, D., Zeinieh, M., Blanc, R., Burk, D. L., Fahiminiya, S., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1549-x · Cited by 196
Self-citationImaging Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3 K27M Mutation
Aboian, M. S., Solomon, D. A., Felton, E., Mabray, M. C., Villanueva-Meyer, J. E., Mueller, S., & Cha, S. (2017) · American Journal of Neuroradiology · doi:10.3174/ajnr.a5076 · Cited by 186
Robinson, G. W., Orr, B. A., & Gajjar, A. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-258 · Cited by 184
Jacob, K., Quang-Khuong, D.-A., Jones, D. T. W., Witt, H., Lambert, S., Albrecht, S., Witt, O., Vezina, C., Shirinian, M., Faury, D., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0127 · Cited by 168
Self-citationA Distinct Spectrum of Copy Number Aberrations in Pediatric High-Grade Gliomas
Bax, D. A., Mackay, A. G., Little, S. E., Carvalho, D. M., Viana‐Pereira, M., Tamber, N., Grigoriadis, A. E., Ashworth, A., Reis, R. M., Ellison, D. W., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0438 · Cited by 160
Louis, D. N., Aldape, K. D., Brat, D. J., Capper, D., Ellison, D. W., Hawkins, C. E., Paulus, W., Perry, A., Reifenberger, G., Figarella-Branger, D. F., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1646-x · Cited by 155
Self-citationVemurafenib in pediatric patients with BRAFV 600E mutated high‐grade gliomas
Bautista, F. J., Paci, A., Minard‐Colin, V., Dufour, C., Grill, J., Lacroix, L., Varlet, P., Valteau‐Couanet, D., & Geoerger, B. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24891 · Cited by 148
H3F3A K27M Mutation in Pediatric CNS Tumors
Gielen, G. H., Gessi, M., Hammes, J., Kramm, C. M., Waha, A., & Pietsch, T. (2013) · American Journal of Clinical Pathology · doi:10.1309/ajcpabohbc33fvmo · Cited by 145
Béchet, D., Gielen, G. H., Korshunov, A., Pfister, S. M., Rousso, C., Faury, D., Fiset, P., Benlimame, N., Lewis, P. W., Lü, C., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1337-4 · Cited by 144
Self-citationErratum: Functionally defined therapeutic targets in diffuse intrinsic pontine glioma
Grasso, C. S., Tang, Y., Truffaux, N., Berlow, N., Liu, L., Debily, M.-A., Quist, M. J., Davis, L. E., Huang, E., Woo, P. J., et al. (2015) · Nature Medicine · doi:10.1038/nm0715-827a · Cited by 138
Broniscer, A., Tatevossian, R., Sabin, N. D., Klimo, P. D., Dalton, J., Lee, R. P., Gajjar, A. J., & Ellison, D. W. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12093 · Cited by 114
Gessi, M., Gielen, G. H., Dreschmann, V., Waha, A., & Pietsch, T. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1463-7 · Cited by 108
Evidence of H3 K27M mutations in posterior fossa ependymomas
Gessi, M., Capper, D., Sahm, F., Huang, K. T. L., von Deimling, A., Tippelt, S., Fleischhack, G., Scherbaum, D., Alfer, J., Juhnke, B.-O., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1608-3 · Cited by 94
Self-citationMYB upregulation and genetic aberrations in a subset of pediatric low-grade gliomas
Tatevossian, R., Tang, B., Dalton, J., Forshew, T., Lawson, A. R. J., Ma, J., Neale, G. A. M., Shurtleff, S. A., Bailey, S., Gajjar, A. J., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0763-1 · Cited by 89
Huillard, E., Hashizume, R., Phillips, J. J., Griveau, A., Ihrie, R. A., Aoki, Y., Nicolaides, T. P., Perry, A., Waldman, T. A., McMahon, M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117255109 · Cited by 87
Gessi, M., Gielen, G. H., Hammes, J., Dörner, E., Mühlen, A. Z., Waha, A., & Pietsch, T. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-1040-z · Cited by 74
on behalf of the members of the SIOPE DIPG Network, van Zanten, S. E. M. V., Baugh, J., Chaney, B., de Jongh, D., Aliaga, E. S., Barkhof, F., Noltes, J., Wolf, R. D., Dijk, J. V., et al. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2363-y · Cited by 71
Self-citationGliomatosis cerebri in children shares molecular characteristics with other pediatric gliomas
Broniscer, A., Chamdine, O., Hwang, S. N., Lin, T., Pounds, S. B., Onar‐Thomas, A., Shurtleff, S. A., Allen, S. J., Gajjar, A. J., Northcott, P. A., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1532-y · Cited by 50
Baugh, J., Bartels, U. K., Leach, J. L., Jones, B. V., Chaney, B., Warren, K. E., Kirkendall, J., Doughman, R., Hawkins, C. E., Miles, L., et al. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2372-5 · Cited by 44
Tumor development in three patients with Noonan syndrome
Fryssira, H., Leventopoulos, G., Psoni, S., Kitsiou‐Tzeli, S., Stavrianeas, N. G., & Kanavakis, E. (2007) · European Journal of Pediatrics · doi:10.1007/s00431-007-0636-3 · Cited by 43
Pilocytic astrocytoma in a child with Noonan syndrome
Schuettpelz, L. G., McDonald, S., Whitesell, K., Desruisseau, D. M., Grange, D. K., Gurnett, C. A., & Wilson, D. B. (2009) · Pediatric Blood & Cancer · doi:10.1002/pbc.22193 · Cited by 33
Kieran, M. W., Bouffet, É., Tabori, U., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw435.09 · Cited by 19
Cited by
Primary brain tumours in adults
Lapointe, S., Perry, A., & Butowski, N. A. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30990-5 · Cited by 1,366
Glioma epigenetics: From subclassification to novel treatment options
Gusyatiner, O., & Hegi, M. E. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.010 · Cited by 541
Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations
Bouffet, E., Hansford, J. R., Garrè, M. L., Hara, J., Plant-Fox, A., Aerts, I., Locatelli, F., van der Lugt, J., Papusha, L., Sahm, F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303815 · Cited by 296
Triple conjugated carbon dots as a nano-drug delivery model for glioblastoma brain tumors
Hettiarachchi, S. D., Graham, R. M., Mintz, K. J., Zhou, Y., Vanni, S., Peng, Z., & Leblanc, R. M. (2019) · Nanoscale · doi:10.1039/c8nr08970a · Cited by 294
Metadata
- Authors
- Sturm, D., Pfister, S. M., & Jones, D. T. W.
- Venue
- Journal of Clinical Oncology
- Published
- 2017-07-20
- Volume
- 35
- Issue
- 21
- Pages
- 2370-2377
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2678747063
- Cited by
- 339
- References
- 80
- FWCI
- 10.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.